CLINICAL EVALUATION OF CARPHENAZINE AND PIPERACETAZINE IN PREVIOUSLY PLACEBO-TREATED CHRONIC SCHIZOPHRENICS
Abstract
Carphenazine and piperacetazine, two new phenothiazines, were given to 80 chronic schizophrenic patients for 4 to 9 months. These patients had previously served as control subjects in a controlled drug evaluation and had not improved.
A global rating of moderate or marked improvement over their pre-study status was observed in 73% of the patients. There were no statistically significant differences between the drugs in degree of improvement or incidence of extrapyramidal reactions. Both drugs were considered effective phenothiazines for the chronic schizophrenic patient.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
